A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Clinical trial NCT01178073 · COMPLETED

Trial details

NCT number: NCT01178073
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hypertension, Pulmonary

Start date: 2010-10-01
Primary completion: 2014-07-31
Enrollment: 610

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.